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Objectives: The aim of our study is to assess the frequency of detection of PET-positive 
computed tomography (CT)-negative skeletal metastases (SM) and determine the 
impact of such detection on staging and/or management in patients who had FDG PET/
CT as part of the cancer work-up.
Methods: We retrospectively reviewed 2000 18F-FDG PET/CT scans of known cancer 
patients. A log was kept to record cases of suspected SM with or without bone changes 
from the low-dose non-contrast CT. The presence or absence of SM was evaluated 
based on available pathological and clinical data. The impact of detection of such lesions 
on cancer staging and/or management was evaluated by a board certified oncologist.
results: Of the 2000 cases, 18F-FDG PET/CT suggested SM in 146/2000 (7.3%). Of 
those 146 cases, 105 (72%) were positive on both PET and CT. The remaining 41 (28%) 
had PET-positive CT-negative bone lesions. SM was confirmed in 36/41 (88%) PET-
positive/CT-negative cases. This was based on biopsy, imaging, or clinical follow-up. 
The detection of PET-positive CT-negative SM did not change staging or management 
in 7/36 (19.4%). However, staging and/or management was affected in 29/36 (80.6%).
conclusion: SM is not uncommon in 18F-FDG PET/CT, as it accounts for 146/2000 
(7.3%) of cases. PET demonstrated FDG-avid SM without a CT abnormality in at least 
36/146 (25%). Patients staging and/or management changed in 29/36 (80.5%). We 
concluded that 18F-FDG PET is sensitive in the detection of SM with significant impact 
on staging and/or management.
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inTrODUcTiOn
Early diagnosis of cancer remains to be of paramount importance to maximize a patient’s long-term 
survival and reduce various neurological, hematological, and orthopedic complications that may 
arise. Skeletal metastasis (SM) is a frequently encountered and important complication of cancer 
which can lead to intolerable pain. Bone metastases are strongly associated with increased risk of 
death and increased risk of skeletal-related events (SREs) (1, 2). SREs are associated with increased 
morbidity, increased treatment costs, and reduced quality of life (3, 4). Skeletal metastases occur 
FigUre 1 | a graph demonstrated total number of scans that were 
reviewed 2000. Of those, 146 had suspected SM by PET and CT. However, 
41 cases were only positive by PET.
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in more than 50% of malignant tumors and up to 70% of breast 
cancer patients (5, 6). Patients with renal cell carcinoma (RCC) 
and SM demonstrated unfavorable prognosis in which more than 
50% of patients die within the first year of diagnosis of SM (7–10). 
The detection of SM might affect cancer staging and follow-up, as 
it can affect the treatment plan. This is particularly true in breast, 
prostate, and lung cancer patients, which are the most common 
malignancies in the United States, with a profound impact on 
patient prognosis (11–15). Whole-body 18F-FDG PET/CT allows 
for the metabolic, anatomic, and morphological characterization 
of suspected bone lesions (16, 17). Studies have shown that the 
higher sensitivity and specificity of 18F-FDG PET/CT in the 
detection of metastasis as well as the impact on tumor staging 
makes it superior to other imaging modalities (18, 19). Although 
computed tomography (CT) is a standard imaging modality in 
cancer imaging, it may fail to detect metastasis, which is confined 
to the bone marrow or to the cortex without visible bone destruc-
tion (20, 21). The purpose of our study is to retrospectively assess 
the frequency of detection of PET-positive/CT-negative SM and 
determine the impact of its detection on cancer staging and/or 
management in patients who had 18F-FDG PET/CT as part of 
their cancer work-up.
MaTerials anD MeThODs
Patient selection
After obtaining Saint Louis University Institutional Review 
Board (IRB) approval, we retrospectively reviewed 2000 con-
secutive 18F-FDG PET/CT scans of known cancer patients. 
The vast majority of patients had top of the head to bottom of 
the feet 18F-FDG PET/CT, as it is the standard of care in our 
institution. A log was kept for cases with suspected SM. PET-
positive cases were further evaluated for the presence of bone 
window changes in the CT. The presence or absence of SM in 
PET-positive/CT-negative cases was determined based on all 
available pathological and clinical data. The impact of detection 
of SM on cancer staging and/or management was evaluated by a 
board certified oncologist.
PeT/cT scanning
18F-FDG PET/CT scans were acquired using PET/CT scanner 
(Gemini TF; Philips Medical Systems) with an axial co-scan 
range of 193  cm. Per institutional protocol, all patients were 
instructed to fast at least 4 h prior to receiving the radiophar-
maceutical injection. Blood glucose level was <200  mg/dl in 
all patients. On the day of the exam, intravenous injection of 
5.18 MBq/kg (0.14 mCi/kg) of F18-FDG was administrated. For 
the uptake phase, patients sat in a quiet room without talking for 
about 60 min.
cT scanning
The CT component of the PET/CT scanner has 64 multidetec-
tor helical CT with a gantry port of 70  cm. The parameters of 
CT detectors were set as follow for 20–21 bed acquisitions: 
120–140 kV and 33–100 mAs (based on body mass index), 0.5 s 
per CT rotation, pitch of 0.9, and 512 ×  512 matrix data were 
used for image fusion and the generation of the CT transmission 
map. The CT images were obtained without oral or IV contrast 
administration according to the standard PET/CT protocol at our 
institution.
PeT scanning and image Processing
The PET component of the PET/CT scanner is composed of lute-
tium–yttrium oxyorthosilicate (LYSO)-based crystal. Emission 
scans were acquired at 1–2 min per bed position. The FOV was 
from the top-of-head to the bottom-of-feet in vast majority of 
patients. The three-dimensional (3D) whole-body WB acquisi-
tion parameters were 128 ×  128 matrix and 18  cm FOV with 
a 50% overlap. Processing used the 3D Row Action Maximum 
Likelihood Algorithm (RAMLA) method. Total scan time per 
patient was approximately 20–45 min.
image analysis
PET/CT images were retrospectively evaluated on the Gemini 
TF extended brilliance workstation (EBW) by a board certified 
nuclear medicine physician and a fellowship trained radiologist. 
Cases were categorized into two groups: the first group was cases 
with PET-positive and CT-positive bone lesions, in which the CT 
of the PET/CT demonstrated morphological changes whether 
lytic, sclerotic, or mixed. The second group was PET-positive 
and CT-negative for bone lesions, in which the CT of the PET/
CT failed to demonstrate definite morphological bone or bone 
marrow changes. No minimum size, number, or standardized 
uptake value criterion was assigned to the SM for inclusion into 
the study. A thorough review of the medical records, including 
clinical notes, pathology reports, and radiology reports, was per-
formed by a board certified oncologist to confirm the diagnosis 
of SM and convey the impact of its detection on cancer staging 
and/or management.
resUlTs
Of the 2000 cases, 18F-FDG PET/CT suggested bone metastases 
in 146/2000 (7.3%). In those 146 cases, 105 (72%) were positive 
on both PET and CT. The remaining 41 (28%) had PET-positive/
CT-negative bone lesions (Figure  1). SM was confirmed in 
FigUre 2 | a 56-year-old male diagnosed with stage iiic adenocarcinoma of the ascending colon status post right hemicolectomy. Follow-up, 
18F-FDG PET demonstrated L5 FDG-avid lesion (green arrows) with no corresponding bone changes in the CT. This finding upstaged his cancer to stage IV. Patient 
received XRT and offered hospice.
FigUre 3 | a 34-year-old female diagnosed with right breast cancer. 
18F-FDG PET demonstrated widespread disease with PET-positive 
CT-negative SM. The FDG-avid left iliac bone and sacral lesions 
demonstrated no bone changes in the CT (green arrows). In this case, there 
was no change in staging; however, BMA was offered.
FigUre 4 | a 53-year-old male diagnosed with diffuse large B-cell 
lymphoma with multiple FDg-avid lesions above and below the 
diaphragm. There were PET-positive CT-negative femoral lesions (green 
arrows). Patient had a full dose CT which was negative for SM. There was no 
change in staging but XRT and BMA were offered.
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36/41 (88%) PET-positive/CT-negative cases. This was based on 
biopsy, imaging, or clinical follow-up. The primary malignancies 
in these 36 patients included: breast cancer (n = 8), lymphoma 
(n = 7), lung cancer (n = 6), melanoma (n = 4), leukemia (n = 3), 
multiple myeloma (n  =  2), gastrointestinal cancers (n  =  2), 
and others (n = 4). Of the remaining 5/41 (12%), SM was not 
confirmed since one patient had a negative bone biopsy and the 
other four patients had no follow-up. The impact of detection 
of PET-positive CT-negative SM on staging and/or management 
was determined by a board certified oncologist. The detection of 
PET-positive/CT-negative SM did not change staging or man-
agement in 7/36 (19.4%), because these patients had widespread 
disease. In total, staging and/or management was affected in 
29/36 (80.6%). This is further divided into patients with a change 
in staging and management in 4/36 (11%), change in staging 
only in 1/36 (3%), and change in management only in 24/36 
(67%) (Figures 2 and 3). The change in management was in the 
form of addition or change in chemotherapy in 16 patients, addi-
tion of bone-modifying agents (BMA) in 12 patients, 11 patients 
received radiotherapy (XRT) to their bone metastasis, 2 patients 
had orthopedic fixation, and hospice was offered for 4 patients 
(Figures 4 and 5; Table 1).
DiscUssiOn
Skeletal metastasis is a serious complication of malignant tumors 
with a significant impact on quality of life. It causes several seri-
ous complications that have emerged as a collection of defined 
SREs including pathological fractures, spinal cord compression, 
the need for surgery or radiation for a symptomatic bone lesion, 
and hypercalcemia of malignancy (21, 22). Although the exact 
incidence of SM in the broad population is unknown, it is esti-
mated that skeletal involvement is present in more than half of 
those deaths resulting from advanced cancer (23).
18F-FDG PET/CT demonstrated higher sensitivity and 
specificity in the detection of SM. This additional information 
4Ahmed et al. PET Positive CT Negative Skeletal Metastasis
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for tumor staging makes it superior to other imaging modalities 
(18, 19). In a study done by Nakai et al., they described invisible 
SM which was not visualized by CT but demonstrated increased 
FDG uptake by PET. They concluded that 18F-FDG PET/CT has 
higher sensitivity than CT in the detection of microscopic early 
SM and attributed these findings to high glucose metabolism by 
tumor cells (20). In a retrospective study, Uchida et al. evaluated 
the efficacy of 18F-FDG PET/CT in the detection of suspected 
bone marrow metastases in the spine and compared it to bone 
scan. In their study, the CT of the 18F-FDG PET/CT was able 
to characterize only 31–32% of bone marrow metastases using 
all available resources, whereas 68–69% went undiagnosed 
using CT (21). Chang et  al., in a meta-analysis, described 
increased sensitivity and specificity of 18F-FDG PET/CT in the 
detection of bone metastases from lung cancer compared with 
conventional bone scan. They reported a sensitivity of 93% and 
specificity of 95% by PET compared with sensitivity of 87% and 
specificity of 82% by bone scan (19). In our study, we compared 
the sensitivity of PET to low-dose CT of the PET/CT in the 
detection of SM.
Our study demonstrated that PET can show an FDG-avid 
SM without a CT abnormality in at least 36/146 (25%) of cases. 
We related the discrepancy between PET and CT in the detec-
tion of SM to the mechanism by which FDG is accumulated into 
the SM by viable and metabolically active tumor cells, which 
is visible by PET before the detection of anatomic changes 
in the CT. Detection of such lesions changed staging and/or 
management in 29/36 (80.6%) of patients who needed special 
treatment to SM. Although we did not evaluate the effect of the 
detection of SM on overall survival (OS), research studies found 
that detection of SM may have an impact on prognosis and 
OS in some cancers. This is particularly true in breast cancer 
patients with bone marrow metastases and is even worse if it is 
complicated by pathological fracture (24). Demir et al. reported 
that the median survival time after the diagnosis of bone 
marrow metastases was 6.43  months which was significantly 
prolonged after systemic therapy (17.3 versus 0.93 months, 95% 
CI; p <  0.001) (25). These findings are similar to our results, 
in which two patients demonstrated bone marrow metastases 
detect by PET and both passed away a few months after the 
diagnosis of marrow metastases. In addition, 18F-FDG PET/
CT aided in diagnosis of SM by directing the site of bone 
marrow biopsy as in the patient in Figure 5 in which the bone 
marrow biopsy was negative at the iliac region and positive at 
the right femur. We did not evaluate the effect of detection of 
PET-positive, CT-negative SM in prostate cancer patients. The 
growing use of (18)F sodium fluoride [(18)F NaF] (PET/CT) 
in the detection of SM in prostate cancer patients, especially 
those with rising PSA level and negative bone scan, resulted in 
under representation of prostate cancer patients in our FDG 
PET/CT scans. Studies have shown that 18F NaF PET/CT is 
more sensitive than both 99mTc-MDP bone scintigraphy and 
FigUre 5 | a 57-year-old female diagnosed with chronic 
myelogenous leukemia status post allogenic bone marrow stem cell 
transplant and widespread disease. 18F-FDG PET demonstrated intense 
focal uptake in the intertrochanteric region of the proximal right femur with no 
corresponding bone changes in the CT (green arrows). The patient had MRI 
with contrast which demonstrated marrow replacing lesion. Patient received 
XRT, BMA, and had orthopedic fixation. In addition, 18F-FDG PET directed 
the biopsy site for this patient.
TaBle 1 | Patients in whom the detection of PeT-positive cT-negative sM 
change staging and/or management.
Patient 
no.
age 
(years)
sex Type of  
primary tumor
change  
in stage
change in 
management
1 59 M Esophageal No Yes
2 86 F Breast No Yes
3 49 F Melanoma No Yes
4 81 M Head and neck No Yes
5 57 M Lung No Yes
6 30 M Lymphoma No Yes
7 57 F Lung Yes III → IV Yes
8 63 M GI YES IIIC → IV Yes
9 48 M Melanoma No Yes
10 62 F breast No Yes
11 74 F Multiple myleoma No Yes
12 61 M Lymphoma No Yes
13 36 F Breast No Yes
14 52 F Germ cell No Yes
15 73 F Breast No Yes
16 71 F Lymphoma No Yes
17 62 M Lung No Yes
18 79 M Lung No Yes
19 68 M GI No Yes
20 55 M Lymphoma No Yes
21 66 F Lung Yes III → IV No
22 69 F Breast No Yes
23 80 F Breast NO Yes
24 53 F Lung Yes III → IV Yes
25 58 F Leukemia NO Yes
26 57 F Lung No Yes
27 59 M GI Yes IIIC → IV Yes
28 70 M Melanoma No Yes
29 77 M MM No Yes
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18F-FDG PET/CT in the detection and differentiation of SM 
from degenerative changes in prostate cancer patients (26–29).
Our study is not without limitations. We compared the sensi-
tivity of PET to the low-dose CT of the PET/CT because it is the 
standard of care in our institution. Indeed, most of the patients 
did not have full dose diagnostic CT available to compare to the 
PET/CT. However, it is not likely that the diagnostic accuracy 
of contrast CT would have been significantly better than on 
low-dose non-contrast CT. Two of the patients had full dose 
diagnostic CT done within a month from the 18F-FDG PET/CT 
and neither demonstrated corresponding changes in CT bone 
window (Figures 4 and 5). Another limitation is that our study 
is based solely on the findings of PET/CT without correlation 
with other imaging modalities. This is related to the retrospec-
tive nature of our study that made us rely more on clinical and/
or pathological confirmation of SM. Finally, the relatively small 
number of PET-positive/CT-negative bone metastases did not 
allow evaluation of the possible impact on staging.
cOnclUsiOn
In our study, SM was not uncommon in 18F-FDG PET/CT, as 
it accounts for 146/2000 (7.3%) of our cases. PET demonstrated 
FDG-avid SM without a CT abnormality in at least 36/146 (25%) 
which resulted in a staging and/or management change in 29/36 
(80.5%). We concluded that 18F-FDG PET may be sensitive in 
the detection of SM with a significant impact on patient staging 
and/or management.
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